Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
Parke-Davis Research Unit, Addenbrookes Hospital Site, Cambridge, UK.
J
J
Hughes
J C
JC
Hunter
G N
GN
Woodruff
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002766:Cholecystokinin / Q000737:chemistry / Q000494:pharmacology / Q000502:physiology*; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D008536:Meglumine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000502:physiology; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism*; D019966:Substance-Related Disorders / Q000188:drug therapy; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D014151:Anti-Anxiety Agents; D007211:Indoles; D011949:Receptors, Cholecystokinin; C065599:PD 134308; D005680:gamma-Aminobutyric Acid; D008536:Meglumine; D002766:Cholecystokinin